For decades, phentermine was the go-to prescription weight-loss medication in the United States. Inexpensive, widely available, and modestly effective, it helped millions of patients kickstart weight loss — often as part of short-term diet programs. Then GLP-1 receptor agonists like semaglutide arrived, and the weight-loss pharmacotherapy landscape shifted dramatically.

Today, many patients find themselves weighing two very different options: the tried-and-true stimulant phentermine, or the newer GLP-1 class represented by semaglutide (sold under brand names Ozempic and Wegovy). This guide breaks down exactly how they compare — in terms of mechanism, efficacy, safety, duration, cost, and who is best suited for each.

How Each Drug Works

Phentermine is a sympathomimetic amine — chemically related to amphetamines — that works primarily by stimulating the central nervous system to suppress appetite. It triggers the release of norepinephrine in the hypothalamus, blunting hunger signals. It may also have modest effects on dopamine and serotonin. The result is a stimulant-like effect: reduced appetite, increased energy, and sometimes heightened alertness. Phentermine acts quickly — effects are noticeable within the first week.

Semaglutide is a GLP-1 receptor agonist that mimics a naturally occurring gut hormone called glucagon-like peptide-1. Rather than overriding hunger through stimulation, semaglutide works through multiple physiological pathways:

  • Activates GLP-1 receptors in the brain that regulate hunger and satiety
  • Slows gastric emptying, prolonging the feeling of fullness after meals
  • Reduces food cravings, particularly for highly palatable foods
  • Improves insulin sensitivity and reduces post-meal blood sugar spikes

Where phentermine essentially overrides hunger through neurochemical stimulation, semaglutide recalibrates the body's regulatory systems in a more physiologically integrated way.

Efficacy: How Much Weight Do You Actually Lose?

This is where the comparison becomes stark. Both drugs reduce weight — but the magnitude of effect is very different.

Phentermine efficacy: Clinical trials and real-world data show phentermine produces average weight loss of 3–7% of body weight over 12 weeks when used as a short-term treatment. For a 200-pound person, that's 6–14 pounds. Results tend to plateau as the body adapts to the stimulant effect, and weight is often regained when the medication is stopped.

Semaglutide efficacy: The landmark STEP trials demonstrated average weight loss of 12–17% of body weight over 68 weeks with semaglutide 2.4 mg. For a 200-pound person, that's 24–34 pounds — often representing a transformative change in health status. Crucially, weight loss with semaglutide continues to accumulate over many months, rather than plateauing at 12 weeks.

Head-to-head comparison studies are limited, but the available data consistently shows semaglutide — and GLP-1s generally — producing approximately 2–3 times more weight loss than phentermine over comparable timeframes.

Side Effect Profiles

Both drugs have well-established side effect profiles that differ substantially in character:

Phentermine side effects are largely stimulant-related:

  • Increased heart rate and elevated blood pressure
  • Insomnia and sleep disruption (a major clinical concern)
  • Dry mouth
  • Anxiety, irritability, or nervousness
  • Headache
  • Potential for dependence and withdrawal (though lower than amphetamines)

Because of its cardiovascular effects, phentermine is contraindicated in patients with heart disease, uncontrolled hypertension, hyperthyroidism, or a history of stimulant misuse. It's a Schedule IV controlled substance.

Semaglutide side effects are primarily gastrointestinal:

  • Nausea (most common — affects up to 44% of users, usually early in treatment)
  • Vomiting
  • Diarrhea or constipation
  • Stomach discomfort
  • Decreased appetite (usually desired)

GI side effects from semaglutide typically diminish within 4–8 weeks as the body adapts, especially with gradual dose escalation. Semaglutide has no cardiovascular stimulant effects and — based on the large SELECT trial — actually reduces cardiovascular risk in high-risk patients, a finding that has no parallel with phentermine.

Duration of Use

One of the most clinically important distinctions between these medications is how long they're designed to be used:

Phentermine is FDA-approved only for short-term use — typically 12 weeks or less. The label explicitly states it should not be used long-term. There's a regulatory and clinical reason for this: it's a stimulant with addiction potential, and its effectiveness wanes over time as tolerance develops.

Semaglutide is approved for chronic, long-term treatment of obesity — reflecting the modern medical understanding that obesity is a chronic disease requiring ongoing management. The STEP 4 extension trial demonstrated that patients who discontinued semaglutide regained most of their lost weight, while those who continued treatment maintained their results. This underscores that semaglutide is a long-term medication, not a short-term fix.

Who Is Each Drug Right For?

Phentermine may be appropriate for:

  • Patients who need a short-term jumpstart and have no cardiovascular contraindications
  • Those who cannot afford or access GLP-1 medications
  • Younger, otherwise healthy patients with mild obesity who want a brief appetite-suppression tool alongside intensive lifestyle changes

Semaglutide is generally better suited for:

  • Patients with BMI ≥ 30, or BMI ≥ 27 with weight-related health conditions
  • Those who need sustained, significant weight loss (not just a short-term boost)
  • Patients with type 2 diabetes or metabolic syndrome (semaglutide also improves glycemic control)
  • Individuals with cardiovascular risk factors (semaglutide has demonstrated cardiovascular benefit)
  • Anyone with a history of heart disease, arrhythmia, or uncontrolled hypertension (phentermine is contraindicated)

Cost Comparison

Cost is one area where phentermine has a significant advantage — at baseline:

  • Phentermine: Generic tablets cost as little as $10–$30 per month. It is one of the cheapest prescription weight-loss medications available.
  • Brand-name semaglutide (Wegovy/Ozempic): $900–$1,350 per month without insurance — a major access barrier.
  • Compounded semaglutide via telehealth: $199–$350 per month through programs like Truventa Medical's weight loss program — dramatically reducing the cost gap.

When weighing cost, it's worth considering the long-term picture. Phentermine is cheap but produces limited, temporary results. Semaglutide at $250/month delivered through a telehealth platform represents meaningful investment in a treatment that can produce 3–4 times more weight loss and has demonstrated metabolic and cardiovascular benefits that translate to reduced long-term healthcare costs.

Access to compounded semaglutide through Truventa Medical has made GLP-1 therapy realistic for patients who previously couldn't consider it. Our all-inclusive program covers provider consultation, personalized dosing, ongoing support, and medication delivery — no insurance required.

The Bottom Line: Why GLP-1s Are Considered Superior Long-Term

Phentermine remains a useful tool in specific, limited circumstances — primarily as a short-term adjunct for patients who are otherwise good candidates. But in virtually every dimension that matters for sustainable weight management — magnitude of weight loss, long-term durability, metabolic benefits, cardiovascular safety, and tolerability — semaglutide and the GLP-1 class are superior.

This isn't a fringe opinion. The American Gastroenterological Association, the Obesity Society, and major endocrinology guidelines now recommend GLP-1 receptor agonists as first-line pharmacotherapy for obesity in eligible patients. The era of short-term stimulant-based weight-loss programs is giving way to a new standard of care — one that treats obesity as the chronic, complex disease it is.